+/- 0##8##2##(1990-02#8)
0##12##1##(1990-02#10)(1990-4#2)
02##2##1##(1990-02#2)
05##2##1##(1990-02#2)
06##3##1##(1990-02#3)
1##5##1##(1990-02#5)
10##2##1##(1990-02#2)
12##3##1##(1990-02#3)
16##2##1##(1990-02#2)
29##2##1##(1990-02#2)
3##3##1##(1990-02#3)
4##2##1##(1990-02#2)
4-epi-doxorubicin and mitomycin C##2##4##(1990-02#2)
4-epi-doxorubicin##4##1##(1990-02#4)
5##2##1##(1990-02#1)(1990-3#1)
5-fluorouracil##3##1##(1990-02#3)
7##4##1##(1990-02#4)
8##2##1##(1990-02#2)
A clinical##2##2##(1990-02#1)(1990-3#1)
A##6##1##(1990-02#4)(1990-3#1)(1990-4#1)
Among##2##1##(1990-02#2)
An##2##1##(1990-3#1)(1991-1#1)
Down's syndrome##5##2##(1990-02#5)
Down's##6##1##(1990-02#6)
ELI##5##1##(1990-02#5)
Ehlers-Danlos syndrome##2##2##(1990-02#2)
HIV infection in##2##3##(1991-1#2)
HIV##4##1##(1991-1#4)
In both RES and ELI MOs##2##6##(1990-02#2)
In##3##1##(1990-02#2)(1990-4#1)
MOs (7##2##2##(1990-02#2)
MOs##7##1##(1990-02#7)
NADPH oxidase##3##2##(1990-02#3)
Na+##2##1##(1990-02#2)
Na+/H+ antiport activity##2##3##(1990-02#2)
Na+/H+ antiport##3##2##(1990-02#3)
RES and ELI MOs##4##4##(1990-02#4)
RES and##5##2##(1990-02#5)
RES##6##1##(1990-02#6)
TPA##4##1##(1990-02#4)
TPA-induced##2##1##(1990-02#2)
The authors##4##2##(1990-02#4)
The average##2##2##(1990-02#2)
The##24##1##(1990-02#21)(1990-3#1)(1990-4#1)(1991-1#1)
This##3##1##(1990-02#2)(1990-3#1)
We##2##1##(1990-02#2)
a high##2##2##(1990-02#2)
a new##2##2##(1990-02#1)(1991-1#1)
a routine##2##2##(1990-02#2)
a##35##1##(1990-02#27)(1990-3#2)(1990-4#4)(1991-1#2)
about##2##1##(1990-02#1)(1990-3#1)
abusers##3##1##(1991-1#3)
acid##5##1##(1990-02#5)
activated##2##1##(1990-02#2)
activities##2##1##(1990-02#2)
activity of##2##2##(1990-02#2)
activity##8##1##(1990-02#8)
adrenocorticotropic hormone##2##2##(1990-02#2)
adrenocorticotropic##4##1##(1990-02#4)
advanced gastric cancer##2##3##(1990-02#2)
advanced##3##1##(1990-02#3)
after birth##2##2##(1990-02#2)
after the##2##2##(1990-02#2)
after##9##1##(1990-02#9)
age##2##1##(1990-3#1)(1991-1#1)
alkalinization##2##1##(1990-02#2)
all##2##1##(1990-02#2)
alpha-subunits##2##1##(1990-4#2)
also##3##1##(1990-02#2)(1990-4#1)
amide##2##1##(1990-4#2)
amiloride##2##1##(1990-02#2)
amino acid sequence##2##3##(1990-02#2)
amino acids##2##2##(1990-02#2)
amino##4##1##(1990-02#4)
among##3##1##(1990-3#1)(1991-1#2)
an##5##1##(1990-02#3)(1990-3#2)
analogues##4##1##(1990-02#4)
analysis##3##1##(1990-02#1)(1990-4#2)
and 7##2##2##(1990-02#2)
and in##3##2##(1990-02#2)(1990-3#1)
and its##3##2##(1990-02#3)
and the##6##2##(1990-02#5)(1990-3#1)
and##81##1##(1990-02#56)(1990-3#11)(1990-4#10)(1991-1#4)
aorta##2##1##(1990-02#2)
are##4##1##(1990-02#3)(1990-4#1)
as regards##2##2##(1990-02#2)
as##8##1##(1990-02#7)(1990-4#1)
at the Regional Hospital##2##4##(1990-02#2)
at the##3##2##(1990-02#3)
authentic##3##1##(1990-02#3)
be##6##1##(1990-02#2)(1990-4#4)
been##6##1##(1990-02#4)(1990-3#2)
beta analogues##2##2##(1990-02#2)
beta##6##1##(1990-02#6)
beta-subunits##2##1##(1990-4#2)
between##6##1##(1990-02#3)(1990-4#3)
binding##2##1##(1990-4#2)
buserelin##2##1##(1990-02#2)
but##4##1##(1990-02#3)(1990-4#1)
by TPA##2##2##(1990-02#2)
by a##4##2##(1990-02#3)(1990-4#1)
by the##4##2##(1990-02#3)(1990-3#1)
by##22##1##(1990-02#18)(1990-3#1)(1990-4#2)(1991-1#1)
cDNA clone##2##2##(1990-02#2)
cDNA##3##1##(1990-02#3)
can##3##1##(1990-02#3)
cancer##4##1##(1990-02#4)
candidates for##3##2##(1990-4#3)
case##5##1##(1990-02#2)(1990-3#3)
cases##6##1##(1990-02#6)
caused by##2##2##(1990-02#2)
children##3##1##(1990-02#3)
clinical##3##1##(1990-02#2)(1990-3#1)
cocaine##4##1##(1991-1#4)
colipase##3##1##(1990-02#3)
colipases##2##1##(1990-02#2)
colon##2##1##(1990-02#2)
come##2##1##(1990-02#2)
comparable##2##1##(1990-02#2)
confirmed by##2##2##(1990-02#2)
consistent with a##2##3##(1990-02#2)
corresponding to##2##2##(1990-02#1)(1990-4#1)
corresponding##3##1##(1990-02#2)(1990-4#1)
days##3##1##(1990-02#3)
demonstrated that##2##2##(1990-4#2)
dentistry##2##1##(1990-3#2)
diagnosed##2##1##(1990-02#2)
diagnosis and##3##2##(1990-02#2)(1990-3#1)
diagnosis##4##1##(1990-02#3)(1990-3#1)
did not##2##2##(1990-02#2)
diet##2##1##(1990-02#2)
different##3##1##(1990-02#2)(1990-3#1)
disease##3##1##(1990-02#1)(1990-3#2)
drug##7##1##(1990-02#2)(1991-1#5)
during##2##1##(1990-02#2)
e##2##1##(1990-02#2)
effectiveness of##2##2##(1990-02#2)
effects of##2##2##(1991-1#2)
effects##3##1##(1990-02#1)(1991-1#2)
elderly##3##1##(1990-02#3)
evaluated##2##1##(1990-02#1)(1990-3#1)
examined##3##1##(1990-02#3)
extracellular##2##1##(1990-02#2)
female##2##1##(1990-02#1)(1991-1#1)
fetuses##3##1##(1990-02#3)
fibromuscular##2##1##(1990-02#2)
five##2##1##(1990-02#2)
flexibility##2##1##(1990-4#2)
followed##2##1##(1990-02#2)
following##2##1##(1990-02#2)
for a##2##2##(1990-02#2)
for adriamycin in##2##3##(1990-02#2)
for##11##1##(1990-02#5)(1990-3#1)(1990-4#4)(1991-1#1)
from##10##1##(1990-02#8)(1990-3#2)
hFSH-beta-(33-53)##2##1##(1990-4#2)
had##3##1##(1990-02#3)
has been carried out##2##4##(1990-02#1)(1990-3#1)
has been##4##2##(1990-02#2)(1990-3#2)
has##5##1##(1990-02#3)(1990-3#2)
have##5##1##(1990-02#5)
high##3##1##(1990-02#3)
highly##2##1##(1990-02#1)(1990-4#1)
hormone##4##1##(1990-02#2)(1990-4#2)
hormone-releasing activity##2##2##(1990-02#2)
hormone-releasing##3##1##(1990-02#3)
human interleukin-1 beta##3##3##(1990-02#3)
hypertension##5##1##(1990-02#5)
i##5##1##(1990-02#5)
important##2##1##(1990-02#2)
in NYC drug##2##3##(1991-1#2)
in RES and ELI MOs##2##5##(1990-02#2)
in RES##3##2##(1990-02#3)
in a##2##2##(1990-02#2)
in advanced##2##2##(1990-02#2)
in an##2##2##(1990-3#2)
in part to##2##3##(1990-02#2)
in rats##2##2##(1990-02#2)
in the treatment of##2##4##(1990-02#2)
in the##18##2##(1990-02#14)(1990-3#2)(1991-1#2)
in##73##1##(1990-02#53)(1990-3#6)(1990-4#5)(1991-1#9)
increased##2##1##(1990-02#2)
induced by##2##2##(1990-02#2)
infections##2##1##(1990-02#2)
inhibited##2##1##(1990-02#2)
inhibitor##2##1##(1990-02#2)
initial acidification##2##2##(1990-02#2)
interaction with##3##2##(1990-4#3)
into##2##1##(1990-02#1)(1991-1#1)
intravenous drug abusers (IVDAs)##2##4##(1991-1#2)
intravenous drug##3##2##(1991-1#3)
intravenous##4##1##(1990-02#1)(1991-1#3)
involved##2##1##(1990-02#1)(1990-4#1)
is##7##1##(1990-02#4)(1990-3#3)
it##3##1##(1990-02#2)(1990-3#1)
its##5##1##(1990-02#5)
less pronounced##2##2##(1990-02#2)
less than 0##2##3##(1990-02#1)(1990-4#1)
less##4##1##(1990-02#3)(1990-4#1)
literature##2##1##(1990-02#2)
macrophages##2##1##(1990-02#2)
markedly reduced pyrogenic##2##3##(1990-02#2)
may##3##1##(1990-02#3)
median##2##1##(1990-02#2)
messenger##2##1##(1990-02#2)
mg/m2 i##2##2##(1990-02#2)
might be##2##2##(1990-4#2)
might##3##1##(1990-02#1)(1990-4#2)
mitomycin C##3##2##(1990-02#3)
moderate##2##1##(1990-02#2)
months (range##2##2##(1990-02#2)
months##6##1##(1990-02#6)
municipalities##2##1##(1990-02#2)
new steady-state pHi##2##3##(1990-02#2)
new##3##1##(1990-02#2)(1991-1#1)
not##5##1##(1990-02#4)(1990-3#1)
nutritional##2##1##(1990-02#2)
observed in the##2##3##(1990-02#2)
observed##5##1##(1990-02#5)
of 4-epi-doxorubicin##2##2##(1990-02#2)
of a##3##2##(1990-02#1)(1990-3#1)(1990-4#1)
of caries and periodontal disease##2##5##(1990-3#2)
of chronic bronchitis in elderly patients##2##6##(1990-02#2)
of chronic##3##2##(1990-02#2)(1991-1#1)
of cocaine##2##2##(1991-1#2)
of gestation##2##2##(1990-02#2)
of hFSH-beta##2##2##(1990-4#2)
of hypertension##2##2##(1990-02#2)
of recurrent##2##2##(1990-02#2)
of renovascular hypertension##2##3##(1990-02#2)
of structural##3##2##(1990-4#3)
of the authentic##2##3##(1990-02#2)
of the syndrome##2##3##(1990-02#2)
of the##21##2##(1990-02#21)
of this##3##2##(1990-02#3)
of##102##1##(1990-02#75)(1990-3#8)(1990-4#12)(1991-1#7)
on day##2##2##(1990-02#2)
on days 1##2##3##(1990-02#2)
on the##3##2##(1990-02#3)
on##10##1##(1990-02#7)(1990-3#2)(1991-1#1)
or##4##1##(1990-02#4)
original schedule##2##2##(1990-02#2)
other##5##1##(1990-02#5)
out##3##1##(1990-02#2)(1990-3#1)
pH##3##1##(1990-02#3)
pHi recovery##2##2##(1990-02#2)
pHi reduction##2##2##(1990-02#2)
pHi##11##1##(1990-02#11)
pancreatic colipase##2##2##(1990-02#2)
pancreatic##3##1##(1990-02#2)(1990-4#1)
parameters##2##1##(1990-4#2)
partial##2##1##(1990-02#2)
particular##2##1##(1990-3#1)(1990-4#1)
particularly##2##1##(1990-02#1)(1990-3#1)
patients##10##1##(1990-02#8)(1990-4#1)(1991-1#1)
peptide##2##1##(1990-02#2)
pregnancy##2##1##(1990-02#2)
previous##2##1##(1990-3#1)(1990-4#1)
primary structure##2##2##(1990-4#2)
primary##3##1##(1990-02#1)(1990-4#2)
produced##2##1##(1990-02#1)(1991-1#1)
profile##2##1##(1990-3#1)(1991-1#1)
progression##2##1##(1990-02#2)
proportion of##2##2##(1990-02#2)
prostate cancer##2##2##(1990-02#2)
pyrogenic activity##2##2##(1990-02#2)
pyrogenic##3##1##(1990-02#3)
receptor##4##1##(1990-4#4)
receptor-binding region##2##2##(1990-4#2)
recovery was##2##2##(1990-02#2)
recovery##3##1##(1990-02#3)
reduced the##2##2##(1990-02#2)
reduced##4##1##(1990-02#4)
region in##2##2##(1990-02#1)(1990-4#1)
region##4##1##(1990-02#1)(1990-4#2)(1991-1#1)
regions of##3##2##(1990-3#1)(1990-4#2)
regions##4##1##(1990-3#1)(1990-4#3)
regulation##2##1##(1990-02#2)
renal artery##2##2##(1990-02#2)
renovascular hypertension##3##2##(1990-02#3)
report##3##1##(1990-02#1)(1990-4#1)(1991-1#1)
reported in##2##2##(1990-02#2)
resident##3##1##(1990-02#3)
respectively)##3##1##(1990-02#3)
results##4##1##(1990-02#3)(1990-3#1)
route##2##1##(1990-02#1)(1991-1#1)
routine scan##2##2##(1990-02#2)
routine##4##1##(1990-02#4)
rupture of the##4##3##(1990-02#4)
scan##3##1##(1990-02#3)
schedule##3##1##(1990-02#3)
seasonal##2##1##(1990-02#2)
secondary structure##3##2##(1990-4#3)
sequence##3##1##(1990-02#3)
severe##2##1##(1990-02#1)(1990-3#1)
significant##2##1##(1990-02#1)(1990-4#1)
sodium piperacillin##2##2##(1990-02#2)
specific##2##1##(1990-02#2)
spontaneous rupture of the intestine and large vessels##2##8##(1990-02#2)
spontaneous rupture of the##3##4##(1990-02#3)
spontaneous##4##1##(1990-02#4)
stimulated##3##1##(1990-02#2)(1990-4#1)
stimulation##2##1##(1990-02#2)
structure of the##2##3##(1990-02#2)
structure of##3##2##(1990-02#2)(1990-4#1)
structure##7##1##(1990-02#2)(1990-4#5)
study##7##1##(1990-02#4)(1991-1#3)
subjects##2##1##(1990-02#1)(1990-3#1)
surface probability##3##2##(1990-4#3)
surgical##3##1##(1990-02#3)
syndrome and its##2##3##(1990-02#2)
syndrome##10##1##(1990-02#10)
synthetic peptides##2##2##(1990-4#2)
synthetic##3##1##(1990-02#1)(1990-4#2)
than##3##1##(1990-02#2)(1990-4#1)
that the##2##2##(1990-02#2)
that##12##1##(1990-02#10)(1990-4#2)
the Authors##2##2##(1990-3#2)
the Captopril-Test##2##2##(1990-02#2)
the adrenocorticotropic hormone-releasing##2##3##(1990-02#2)
the cases##2##2##(1990-02#2)
the diagnosis##2##2##(1990-02#2)
the homologous##2##2##(1990-02#1)(1990-4#1)
the present study##2##3##(1990-02#2)
the primary##2##2##(1990-02#1)(1990-4#1)
the respiratory burst##2##3##(1990-02#2)
the syndrome##3##2##(1990-02#3)
the treatment of##3##3##(1990-02#2)(1991-1#1)
the treatment##4##2##(1990-02#3)(1991-1#1)
the##103##1##(1990-02#84)(1990-3#8)(1990-4#6)(1991-1#5)
therefore##2##1##(1990-4#2)
these##4##1##(1990-02#3)(1990-4#1)
thymopentin##2##1##(1990-02#2)
time##3##1##(1990-02#2)(1990-3#1)
to a##3##2##(1990-02#3)
to be##2##2##(1990-02#1)(1990-4#1)
to the##4##2##(1990-02#2)(1990-4#1)(1991-1#1)
to##34##1##(1990-02#26)(1990-3#1)(1990-4#5)(1991-1#2)
total##2##1##(1990-02#2)
trauma##2##1##(1990-02#2)
treated##3##1##(1990-02#3)
treatment with##3##2##(1990-02#3)
treatment##12##1##(1990-02#10)(1991-1#2)
two##2##1##(1990-02#2)
type IV##2##2##(1990-02#2)
ultrasonic##2##1##(1990-02#2)
ultrasound##2##1##(1990-02#2)
use##2##1##(1990-02#1)(1991-1#1)
using##3##1##(1990-02#2)(1990-4#1)
v##3##1##(1990-02#3)
very##2##1##(1990-02#1)(1990-4#1)
was partially##2##2##(1990-02#2)
was##26##1##(1990-02#25)(1990-4#1)
were evaluable##2##2##(1990-02#2)
were suspected to have Down's syndrome after##2##7##(1990-02#2)
were treated with##2##3##(1990-02#2)
were##18##1##(1990-02#16)(1990-4#2)
when##2##1##(1990-02#2)
which##3##1##(1990-02#3)
with Down's syndrome in the##2##5##(1990-02#2)
with a##3##2##(1990-02#3)
with the##5##2##(1990-02#3)(1990-4#2)
with##28##1##(1990-02#22)(1990-4#5)(1991-1#1)